The effect of weight change on kidney cancer patients treated with targeted therapy

A recent retrospective study of 3311 patients with metastatic renal cell carcinoma (RCC) and on first- or second-line targeted therapy clinical trials showed that patients who experience weight loss during treatment have worse outcomes compared with patients with stable weight at 6 and 12 weeks of treatment. Weight loss at 6 weeks after the start […]

read more

Major updates in the management of metastatic kidney cancer

In this video interview, Dr Eric Jonasch from MD Anderson Cancer Center in Houston, Texas, talks about the introduction of immunotherapy and immunotherapy-targeted therapy combinations over the past two years for the first-line treatment of metastatic renal cell carcinoma (RCC). Watch the video interview on Practice Update here

read more

Effectiveness of targeted therapy after immunotherapy in metastatic kidney cancer patients

In this retrospective international study, the effectiveness of targeted therapy following discontinuation of immunotherapy for patients with metastatic renal cell carcinoma (RCC) in the real world was investigated. There were 314 patients in the study; 276 (87.9%) were treated with vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs), such as sunitinib, axitinib and cabozantinib, […]

read more

Real world use of targeted therapies in war veterans with kidney cancer

A retrospective study of the use of targeted therapies for advanced renal cell carcinoma (RCC) in war veterans in the USA reported poorer overall survival outcomes than those from clinical trials, as well as shorter treatment durations for first-line therapies with more frequent adverse events, dose reductions, and drug discontinuations. The study was published in […]

read more

Effect of weight loss during treatment with targeted therapy

This large retrospective study of 3311 patients with metastatic renal cell carcinoma (RCC) was designed to investigate the effect of weight change on overall survival in patients treated with targeted therapy. During 12 weeks after starting first- or second-line treatment with a targeted therapy, 28% of patients had lost weight and 58% had stable weight. […]

read more

Effect of antibiotic use on outcomes with systemic therapies in metastatic kidney cancer

This study, published in European Urology Oncology this week, investigated the impact of antibiotic use on clinical outcomes in patients with metastatic renal cell carcinoma (RCC) treated with systemic anti-cancer drugs. The use of antibiotics alters the microbes living in our guts (gut microbiota), which is a key regulator of immune system. In the study, […]

read more

PD-L1 expression and clinical outcomes with targeted therapy

A recent study published in Clinical Cancer Research analysed tumour tissue samples obtained in a clinical trial to investigate how the expression of the PD-L1 receptor on the tumour cells influenced outcomes in patients with metastatic renal cell carcinoma (RCC) receiving targeted therapy. Positive expression of the PD-L1 receptor on RCC tumour cells was associated […]

read more

Current perspectives on non-clear cell kidney cancer

The majority of kidney cancer (around 80%) is characterised as clear-cell renal cell carcinoma (RCC), while the remaining 20% is non-clear cell RCC. Most of these are papillary RCC, but non-clear cell RCC also includes collecting duct, translocation, chromophobe and a variety of other rare tumour types. Because non-clear cell RCC is relatively rare, data […]

read more

The role of biomarkers in predicting response to treatment in metastatic kidney cancer

This review published in Clinical Genitourinary Cancer summarises the current treatments available for metastatic renal cell carcinoma (RCC), and the data from some of the most recent clinical trials, including CABOSUN, CheckMate 214, IMmotion151, and JAVELIN Renal 100. There is also a discussion about the use of biomarkers as predictors of outcomes for patients with […]

read more

The role of cytoreductive nephrectomy in metastatic kidney cancer

Around 12,500 new cases of renal cell carcinoma (RCC) are diagnosed annually in the UK, and about a third of these cases initially present with cancer that has spread to other parts of the body (non-localised or metastatic). Non-localised RCC has significantly worse 5-year survival outcomes compared with localised disease. The treatment options for patients […]

read more
Showing 1 to 10 of 27 results
  TOP